MangoRx vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: MangoRx scores higher on our rubric, 7.5/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit MangoRx - our pick of these two →or find your match

MangoRx beats MEDVi overall, scoring 7.5/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MangoRx is from $299/mo; MEDVi is $179 first month, then $299/mo. Choose MangoRx for needle-phobic users who want oral-only glp-1 tablets from a publicly traded company. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.

A side-by-side look at MangoRx and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

MangoRx

#22 of 54

7.5/10

Multi-service telehealth platform offering compounded GLP-1 alongside other health services.

Visit MangoRx

MEDVi

#46 of 54

5.7/10

MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.

Visit MEDVi

Feature	MangoRx	MEDVi
Why each one	Oral dissolving tablets exclusively (zero injections) from a publicly traded company (NASDAQ: MGRX) with SEC-level financial transparency.	Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication.
Our Score	7.5/10	5.7/10
Headline Price	from $299/mo	$179 first month, then $299/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Needle-phobic users who want oral-only GLP-1 tablets from a publicly traded company	Users who want both oral and injectable compounded options in one telehealth program
Watch out for	Oral semaglutide at $299/mo runs 2-3x injectable alternatives ($99-149/mo). The premium only makes sense if needles are a hard no for you.	FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
Ranking	#22	#46
Get started	Visit MangoRx	Visit MEDVi

Pros & Cons Compared

MangoRx

Pros

+Oral dissolving tablets exclusively, zero injections for any GLP-1 option
+Publicly traded on NASDAQ (MGRX), SEC-required financial transparency that private competitors can't match
+Semaglutide tablet includes Vitamin B6 to help reduce nausea during treatment
+Free 100% online consultation with no video call required

Cons

−Oral semaglutide at $299/mo runs 2-3x injectable alternatives ($99-149/mo). The premium only makes sense if needles are a hard no for you.
−Early-stage public company with limited revenue; the same SEC filings that provide transparency also show the financial uncertainty reflected in the stock.
−Oral tablets are the only format, with no injectable option if you want higher bioavailability. If you may switch to injections later, pick a platform that carries both.

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping

Cons

−FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
−Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
−The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
−Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Our Verdict

MangoRx edges out MEDVi with a score of 7.5/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MangoRx is from $299/mo; MEDVi is $179 first month, then $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility.